Health Canada approves Qulipta for the prevention of episodic migraine
AbbVie announced at Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults
Qulipta, the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) preventive treatment, marks the latest innovation in AbbVie's migraine portfolio to support Canadians impacted by migraine.
The approval is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of Qulipta in nearly 2,000 patients who experienced 4 to 14 migraine days per month. Qulipta demonstrated statistically significant, clinically meaningful, rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks.
Related news and insights
Pfizer Inc. announced publication of results in The Lancet Neurology from the Phase III pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine